DRIVE-MRT is an integrated solution for theranostics provided by the complementary knowledge, know-how AND GLOBAL COVERAGE of ABX-CRO (Dresden, Germany), Chematech (Dijon, France), Covalab (Lyon, France) and Oncodesign Services (Dijon, France). It covers a full continuum of technologies related to the validation of targets, the generation and optimization of vectors, the radiochemistry and PET/SPECT imaging techniques, small animal and clinical dosimetry, and a dedicated support for regulatory and clinical studies specific to radiopharmaceuticals. The partners have been working together for many years.
ABX-CRO is one of the leading dedicated radiopharmaceutical CROs with offices in the US, Australia, India, South Africa, and the EU having a proven track record to successfully support therapeutic and diagnostic radiopharmaceutical programs from preclinical through phase I - IV.
State of the art comprehensive clinical operations, with integrated image core lab services (technical set-up, dosimetry, image endpoints) are complemented by the full range of support functions specific to radiopharmaceuticals (sourcing, CDMO, IMP logistics), as well as high-class specialist services (strategic and scientific advice, regulatory, medical writing, pharmacovigilance, medical monitoring, data management & statistics)
CheMatech is a leading company specialising in the design and synthesis of bifunctional chelating agents such as DOTA, NOTA and NODAGA derivatives. These molecules are widely used for peptides or antibodies labelling especillay with 67/68Ga, 111In, 64/67Cu. CheMatech offers a wide range of functionalised and protected chelating agents from milligrams to kilograms scale. CheMatech also offers custom syntheses, GMP production of chelators and bioconjugation services.
Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. From target identification to IND filing, the company contributes to the development of innovative therapies in oncology, inflammation and infectious diseases, with high medical needs.
Through integrated capabilities in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology, Oncodesign Services support the R&D programs of customers with a global footprint.
Based in Dijon, France, in the heart of the university and hospital cluster and within the Paris-Saclay cluster, Oncodesign Services has 230 employees in France, Canada and the United States
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.
Eckert & Ziegler - Hosting Partner
With more than three decades of experience in the field, Eckert & Ziegler Medical represents the combined expertise in nuclear medicine, molecular imaging, radiation therapy and beyond.
We complement our wide-ranging portfolio of innovative high-quality technical solutions with the provision of development and contract manufacturing services. With our global network of GMP suites we offer fully licensed radioisotope labs, stable supply arrangements for pharmaceutical radioisotopes, a state-of-the-art infrastructure, and highly experienced staff to support your preclinical and clinical projects.
As a one-stop-shop for all your radiopharmaceutical needs, we offer hot cell solutions, radiochemicals, radiopharmaceuticals, radiosynthesis technology, QC equipment and more.
BIOEMTECH - Innovation Partner
BIOEMTECH is a fast-growing CRO that provides high-quality, cost-effective solutions through the unique combination of preclinical services and molecular imaging instrumentation. BIOEMTECH undertakes full studies for evaluating new compounds in our authorised laboratories. Moreover, BIOEMTECH has developed and commercialised the "eyes", desktop cameras, suitable for whole-body, real-time imaging of radionuclides and dyes in mice. Very recently, BIOEMTECH “eyes” made feasible in vivo imaging of alpha emitters including Pb-212 and Ac-225 in oncological mouse models.
Iotron Medical - Innovation Partner
Iotron Medical is the first and only commercial supplier of copper-67. We are currently
providing this beta-emitting radioisotope to researchers in US, Canada, and Europe, though
a partnership with Canadian Isotope Innovation Corp. Copper-67 is a proven radioisotope for
theranostics, particularly when paired with copper-64 for PET imaging. This theranostic pair
delivers key advantages, including identical in-vivo behavior for imaging and therapy and
optimum half-life for small molecule therapeutics.
Navigo Proteins - Innovation Partner
Navigo Proteins is developing novel targeted radiopharmaceuticals based on its proprietary target binders called Affilin® ligands. Navigo’s Precision Targeting Toolbox enables custom-designing Affilin® Radiotheranostics by combining, mono-, bi- or multi-specific target binders with chelators, imaging/therapy radionuclides and proprietary half-life extending domains, creating the ideal candidate with fine tuneable affinity and pharmacokinetic profile. With a growing portfolio of Affilin® ligands against solid tumors and I/O targets, Navigo is looking for strategic partnerships to advance Affilin®-Radiotheranostics into clinical development.
Trasis - Innovation Partner
Trasis was founded in 2004 by Gauthier Philippart and Jean-Luc Morelle, the designers of the first radiosynthesisers to combine high-yield synthesis and GMP.
They put together their expertise and their knowledge of the radiopharmaceutical industry and founded Trasis, an innovative and forward-looking company. Trasis has now a track-record in developing instruments and methods recognized throughout the world.
At Trasis we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster. To this end, we design, manufacture, sell and support high performance synthesisers, dose preparation equipment, their shielding and accessories. We also develop customised synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs.
Our proven radiopharmaceutical expertise, coupled with our high end instruments allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorisation.
Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities and pharmaceutical companies
PharmaLogic - Innovation Partner
PharmaLogic is a world-class contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other diseases. PharmaLogic has decades of expertise in drug development from discovery to commercialization through atop-tier network of radiopharmacies in North America. The Company seeks to take the lead in the advancement of radiopharmaceutical technology for the benefit of patients worldwide. For more information, visit:
Chelatec - Exhibition Partner
Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech.
With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities.
Specialising in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package: all quality and nonclinical safety data required for translation of a radiopharmaceutical.
PMB-Alcen - Exhibition Partner
PMB is a human-sized company based in France, with a long-standing expertise in brazing dissimilar materials and specialized in the design and manufacture of complex assemblies and sub-assemblies (RF and beamline components, components for X-ray tubes, ceramicmetal assemblies…), as well as particle accelerators and disruptive medical systems like iMiGiNE.
iMiGiNE is an automated radiopharmaceutical production system dedicated to PET radiotracers based on an innovative microfluidic cassette. The system combines an iMiTRACE cyclotron with a robotized iMiLAB radiochemistry room for in-situ. iMiDEV is our R&D synthesizer allowing for radiotracer development and synthesis in the same microfluidic cassettes. Thanks to its 10 years of experience in microfluidics and radiochemistry, PMB is now working on an advanced solution for the scalable synthesis of radiotherapeutics with its partners.
Eczacıbaşı Monrol Nuclear Products - Exhibition Partner
Monrol-Eczacıbaşı Monrol Nuclear Products was founded by Bozlu Holding in 1995 and has continued its activities in partnership with Eczacıbaşı Pharmaceuticals Manufacturing since 2008, while leading the development of nuclear medicine in Turkey since its establishment, is a nuclear medicine company that also carries out its expertise all around the world with high quality standards of radiopharmaceuticals and logistics infrastructure produced with EUGMP quality.
IONETIX - Exhibition Partner
IONETIX is a full-service, end-to-end radiopharmaceutical solutions provider. Utilizing a proprietary cyclotron technology platform, Ionetix develops innovative accelerator solutions to produce medical radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. Ionetix is currently in the process of establishing the first commercial alpha isotope manufacturing and distribution facility dedicated to the production of Actinium-225 (Ac- 225) and Astatine-211 (At- 211). Ionetix will provide isotope production, drug manufacturing and distribution logistics for these alpha isotopes beginning in early 2023
intoDNA - Exhibition Partner
intoDNA is a groundbreaking biotech company revolutionising DNA break detection with STRIDE. We provide DNA damage detection and quality assessment at every stage of targeted therapeutics development pipelines. STRIDE is the first-ever fluorescence-based technology that detects single and double stranded DNA ends directly with astonishing precision, setting a new standard in sensitivity and specificity. New assays have been developed to detect DDR proteins in proximity to DNA breaks.
RPO Scientific - Exhibition Partner
RPO is a radiotheranostic CRO with a focus on early phase FiH radiopharmaceutical drug development in precision oncology. The company has a global preferred site network, and was founded by Prof Dr Richard P Baum and Dr Hugo M L Jansen in order to obtain early phase information regarding the clinical potential of radiotheranostic agents. The traction and success rate of radiotheranostic development is merely determined by its efficacy (therapeutic response) and safety profile in comparison to the standard of care. RPO builds a body of evidence around the early compound, delivers value from limited datasets, expedites drug development routes, and avoids tunnel vision.
PSI CRO - Exhibition Partner
PSI is a unique global CRO with offices and an operational presence of full-time operational staff in more than 50 countries. PSI is headquartered in Switzerland and is fully owned by the management team that created the company in 1995.
PSI is known for its commitment to delivery and service, focus on global pivotal phase II and III trials, as well as exceptionally high repeat business rates.
Biotech and pharma clients that work with PSI on global trials tend to stay with them for decades, which explains the company's stability and steady organic growth supported by exceptionally low staff turnover rates.
PSI's mission is to be the best CRO in the world as measured by their employees, clients, investigators, and vendors.
Scitech - Exhibition Partner
We provide pharmaceutical design and qualification consultancy, as well as qualification and validation for high value manufacturing, research, emerging technologies and highly regulated industries; this includes pharmaceutical, biotechnology, life sciences and radiopharmaceutical industries. We have a multidisciplinary team, with extensive experience across pharmaceutical design and qualification consultancy, cell gene therapy and animal health, to name a few.
Shine - Exhibition Partner
SHINE is a next-generation nuclear technology company, focused on deploying state-of-the-art fusion technology to help solve global problems and create a scalable path toward practical fusion energy. SHINE deploys its safe, cost-effective and environmentally-friendly technology in a step-wise approach, beginning with our systems used for advanced industrial imaging in non-destructive testing of components used in aerospace, defense, transportation, energy and other sectors. SHINE’s proprietary medical isotope production creates Molybdenum 99 and non-carrier-added Lutetium 177 used in tens of thousands of daily procedures to diagnose and treat heart disease and late-stage cancer. For more information, follow SHINE on Facebook, LinkedIn and Twitter.
Senn Chemicals - Event Partner
Senn Chemicals AG is a CDMO from Switzerland with strong technological expertise and project experiences to develop and produce your highly complex cold-radiopharmaceutical products under GMP. Our processes ensure low microbial/endotoxin levels and low elemental impurities in bulk and aliquoted material. We manufacture your chelating agent-containing product according to your specifications and in compliance with current guidelines for substances for pharmaceutical and radiopharmaceutical use. Partner with us for your regulatory submission!
NorthStar Medical Radioisotopes - Event Partner
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company focused on advancing patient care by providing therapeutic and diagnostic radioisotopes, novel radiopharmaceuticals, and customized radiopharmaceutical development services. Its proven management team and environmentally preferable, non-uranium based technologies have made it an emerging leader at the forefront of U.S. medical radioisotope and radiopharmaceutical production. NorthStar is poised to be the first commercial-scale producer of non-carrier added (n.c.a.) actinium-225 (Ac-225) and copper-67 (Cu-67). Its Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) services unit will provide customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their programs.
Minerva Imaging - Event Partner
Minerva Imaging is a scientifically driven CRO and CDMO specialized in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services.
Become a Partner:
Interested in putting your products and services in front of the largest and most engaged audience of TRP professionals?